Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Chief Financial Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 193,688 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 193,688 · Balance 193,688 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 193,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040215 · wk-form4_1780517141.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,688 Underlying: Common Stock · 193,688 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 8,149 | $3.84 | $31,292.16 |
DisclosureSEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,883 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 27,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,166 Underlying: Common Stock · 27,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 27,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009803 · wk-form4_1771536658.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 15,213 | $4.03 | $61,308.39 |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,448 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 26,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 7 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,575 Underlying: Common Stock · 26,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 6 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,901 Underlying: Common Stock · 13,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · derivative · entry 5 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 26,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 13,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:48 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 3,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003147 · wk-form4_1769125714.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 1,303 | $6.49 | $8,456.47 |
DisclosureSEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,298 F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| November 02, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,605 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025. F5 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025. Read SEC document |
| November 02, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 3,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-048858 · wk-form4_1762290943.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: Includes 1,511 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a price of $4.17 Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 14,827 | $4.26 | $63,163.02 |
DisclosureSEC source: 0001628280-25-034531 · wk-form4_1752006603.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,485 F1 · shares: The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the settlement of 44,368 RSUs which vested on January 20, 2025. The settlement occurred on July 3, 2025, as approved by the Issuer's Compensation Committee. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F2 · balance_after: Includes 2,056 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price of $7.21. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 82,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081720 · ownership.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,750 Underlying: Common Stock · 82,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 1,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034006 · ownership.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,702 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 3, 2022, the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025. F3 · derivative.expiration_date: On March 3, 2022, the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 3, 2025. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 1,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034006 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 3, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 26,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,150 Underlying: Common Stock · 26,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 13,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,801 Underlying: Common Stock · 13,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008012 · ownership.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,888 Underlying: Common Stock · 3,889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 44,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-008012 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 12:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 2,113 | $4.75 | $10,036.75 |
DisclosureSEC source: 0000950170-24-141308 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,186 Read SEC document |
| November 21, 2024 Filed Nov 21, 2024 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 3,000 | $6.76 | $20,280.00 |
DisclosureSEC source: 0000950170-24-129735 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,073 Read SEC document |
| November 02, 2024 Filed Nov 6, 2024 00:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-121729 · ownership.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,605 Underlying: Common Stock · 3,605 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 02, 2024 Filed Nov 6, 2024 00:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 3,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-121729 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on November 2, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 11:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 79,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100020 · ownership.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,725 Underlying: Common Stock · 79,725 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072050 · ownership.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024. F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-072050 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 08, 2024 Filed May 9, 2024 00:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 8,334 | $12.00 | $100,008.00 |
DisclosureSEC source: 0000950170-24-056140 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,014 F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 1,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053116 · ownership.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,702 Underlying: Common Stock · 1,702 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 1,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-053116 · ownership.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024. F3 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 01:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 41,705 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046596 · ownership.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,705 Underlying: Common Stock · 41,705 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 29, 2024 Filed May 3, 2024 22:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 506 | $18.50 | $9,361.00 |
DisclosureSEC source: 0000950170-24-053116 · ownership.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,978 F1 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 116,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002121 · doc4.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,310 Underlying: Common Stock · 116,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 116,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002121 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 22:04 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 108,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054546 · doc4.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,312 Underlying: Common Stock · 108,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 22:04 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 108,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054546 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 5,951 | $0.39 | $2,320.89 |
DisclosureSEC source: 0001209191-23-048144 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,291 F1 · kind: These shares were acquired under the Issuer's 2019 Employee Stock Purchase Plan subsequent to the Reporting Person's Form 4 filed on August 22, 2023. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 20:10 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 90,000 | $0.48 | $43,200.00 |
DisclosureSEC source: 0001209191-23-046874 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,340 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.47 to $0.485. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2023 Filed Oct 27, 2023 20:55 UTC Amendment | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 90,000 | $0.48 | $43,200.00 |
DisclosureSEC source: 0001209191-23-053784 · doc4a.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,340 F1 · kind: This amendment is being filed to correct the Transaction Code (as set forth in Box 3). The Form 4, as originally filed, inadvertently reported the Transaction Code as "A." F2 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.47 to $0.485. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 13,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035792 · doc4.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,635 Underlying: Common Stock · 13,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F4 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 34,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035792 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 13,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035792 · doc4.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 34,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035792 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 13:19 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 20,000 | $0.86 | $17,200.00 |
DisclosureSEC source: 0001209191-23-020154 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,614 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.847 to $0.87. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 51,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016835 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,114 Underlying: Common Stock · 51,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 51,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016835 · doc4.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2023 Filed Mar 7, 2023 22:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 11,605 | $0.95 | $11,024.75 |
DisclosureSEC source: 0001209191-23-016835 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,543 Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004610 · doc4.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.